Patrick Flume to Sputum
This is a "connection" page, showing publications Patrick Flume has written about Sputum.
Connection Strength
0.652
-
Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020 07; 19(4):569-574.
Score: 0.164
-
Nontuberculous Mycobacteria in Cystic Fibrosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):383-391.
Score: 0.146
-
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8.
Score: 0.122
-
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842.
Score: 0.044
-
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816.
Score: 0.040
-
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 06; 49(6).
Score: 0.034
-
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
Score: 0.030
-
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49.
Score: 0.028
-
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6.
Score: 0.022
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
Score: 0.021